Skip to content

US · SXTC · DRUG MANUFACTURERS - SPECIALTY & GENERIC

China SXT Pharmaceuticals, Inc. (SXTC) intrinsic value and stock valuation

$2.65as of 2026-11-21 · Mkt cap 45.55K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

China SXT Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values SXTC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SXTC’s statements →

China SXT Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Taizhou, JS 225300 sxtchina.com

How the business is doing

Fiscal 2016–2026, USD

Revenue
$1.07M-25.9% 5y CAGRd
20162026
Net income
-$-6.21M
20162026
Free cash flow
-$-4.02M
20162026
Total equity
$29.7M+13.2% 5y CAGRd
20162026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2026, USD
20262025202420232022
Revenue$1.07M$1.74M$1.93M$1.97M$2.6M
Operating income-$-7.12M-$-2.68M-$-2.52M-$-5.61M-$-5.19M
Net income-$-6.21M-$-3.3M-$-3.1M-$-5.93M-$-5.74M
EPSd-$-9.13M-$-8.25M-$-3.56M-$-21.96M-$-143.5M
Operating cash flow-$-4.02M-$-2.35M-$-1.93M-$-80K-$-2.37M
Capital expenditure-$0.00-$0.00-$-10K-$-70K-$-60K
Free cash flow-$-4.02M-$-2.35M-$-1.94M-$-150K-$-2.44M
Total assets$34.8M$21.7M$23.1M$29.6M$33.6M
Total debt$1.12M$980K$2.65M$3.76M$10.7M
Net debt-$-27.06M-$-17.12M-$-9.42M-$-13.61M-$-4.78M
Total equity$29.7M$15.4M$13.9M$14.7M$16.4M
Cash and short-term investments$28.2M$18.1M$12.1M$17.4M$15.5M
Income statement
20262025202420232022
Revenue$1.07M$1.74M$1.93M$1.97M$2.6M
Cost of revenue$890K$1.37M$1.37M$1.55M$1.35M
Gross profit$180K$370K$550K$430K$1.25M
Research and development expenses$180K$190K$180K$0.00$0.00
Selling, general and administrative expenses$7.13M$3.05M$3.07M$6.03M$6.44M
Other expenses$0.00-$-190K-$-180K$0.00$0.00
Operating expenses$7.31M$3.05M$3.07M$6.03M$6.44M
Cost and expenses$8.2M$4.42M$4.44M$7.58M$7.79M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$60K$650K$540K$480K$40K
Depreciation and amortization$140K$80K$200K$250K$320K
Ebitda-$-6.98M-$-2.57M-$-2.35M-$-5.21M-$-5.05M
Operating income-$-7.12M-$-2.68M-$-2.52M-$-5.61M-$-5.19M
Total other income/expenses, net$1.05M-$-620K-$-580K-$-330K-$-220K
Income before tax-$-6.07M-$-3.3M-$-3.1M-$-5.93M-$-5.41M
Income tax expense$130K$0.00$0.00$0.00$330K
Net income-$-6.21M-$-3.3M-$-3.1M-$-5.93M-$-5.74M
Weighted average shares outstanding$680K$400K$870K$270K$40K
Weighted average diluted shares outstanding$680K$400K$870K$270K$40K
Balance sheet
20262025202420232022
Cash and short-term investments$28.2M$18.1M$12.1M$17.4M$15.5M
Net receivables$3.23M$1.9M$1.35M$1.34M$3.37M
Inventory$2.96M$830K$810K$530K$1.07M
Total current assets$34.5M$21.3M$14.2M$19.5M$22.5M
Property, plant and equipment, net$240K$360K$560K$1.27M$1.59M
Goodwill and intangible assets$10K$10K$20K$30K$40K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$240K$370K$8.89M$10M$11.1M
Total assets$34.8M$21.7M$23.1M$29.6M$33.6M
Accounts payable$500K$1.16M$1.28M$1.38M$1.48M
Short-term debt$420K$770K$2.35M$3.39M$10.7M
Deferred revenue$100K$60K$190K$170K$0.00
Total current liabilities$4.35M$6.01M$8.9M$14.5M$17.1M
Long-term debt$700K$210K$290K$370K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$700K$210K$290K$370K$0.00
Capital lease obligations$50K$180K$240K$310K$0.00
Total liabilities$5.05M$6.22M$9.2M$14.9M$17.1M
Common stock$64.1M$44.5M$4.35M$910K$160K
Retained earnings-$-34.22M-$-28.02M-$-24.71M-$-21.61M-$-15.69M
Accumulated other comprehensive income (loss)-$-200K-$-1.08M-$-1.03M-$-200K$960K
Total equity$29.7M$15.4M$13.9M$14.7M$16.4M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$1.12M$980K$2.65M$3.76M$10.7M
Net debt-$-27.06M-$-17.12M-$-9.42M-$-13.61M-$-4.78M
Cash flow statement
20262025202420232022
Net income-$-6.21M-$-3.3M-$-3.1M-$-5.93M-$-5.74M
Depreciation and amortization$140K$80K$200K$250K$320K
Stock-based compensation$0.00$0.00$350K$550K$0.00
Change in working capital-$-2.39M-$-970K-$-380K$1.42M$1.92M
Accounts receivable-$-1.32M-$-480K-$-320K$910K$800K
Inventory-$-510K-$-10K-$-190K$410K$300K
Accounts payable-$-690K-$-110K-$-30K$10K$0.00
Net cash provided by operating activities-$-4.02M-$-2.35M-$-1.93M-$-80K-$-2.37M
Investments in property, plant and equipment-$-1.25M-$0.00-$-10K-$-70K-$-60K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-1.25M$60K$30K-$-10K-$-50K
Common stock issued$14.3M$2.76M$0.00$2.19M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$14.4M$8.4M-$-2.62M$2.94M$1.63M
Net change in cash$10.1M$6.05M-$-5.29M$1.8M-$-400K
Cash at end of period$28.2M$18.1M$12.1M$17.4M$13M
Operating cash flow-$-4.02M-$-2.35M-$-1.93M-$-80K-$-2.37M
Capital expenditure-$0.00-$0.00-$-10K-$-70K-$-60K
Free cash flow-$-4.02M-$-2.35M-$-1.94M-$-150K-$-2.44M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About China SXT Pharmaceuticals, Inc.

        China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.

        CEO
        Feng Zhou
        Employees
        56
        Beta
        1.82

        Explore

        Frequently asked questions

        What is the intrinsic value of China SXT Pharmaceuticals, Inc. (SXTC)?

        InvestorsCraft does not currently publish an intrinsic value for SXTC. How the IC value is calculated.

        Is SXTC undervalued?

        InvestorsCraft does not publish an undervaluation signal for SXTC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.